Established in June 2013 as a spin-off from the University of Illinois at Chicago, Novalex Therapeutics devlops a novel class of antimicrobials that target drug resistant infections, focusing on developing small molecule antimicrobials that were initially discovered in the academic laboratory setting at UIC. The company currently has two platforms, a novel antibacterial compound that targets the fatty acid biosynthetic pathway enzyme, FabI and is being developed for the treatment of staphylococcal infections, and a novel antiviral that targets the NS3/4A protease of the Hepatitis C Virus.
